Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term soraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Makol, Ankita, Kaur, Harpreet, Sharma, Sakshi, Kanthaje, Shruthi, Kaur, Ramanpreet, Chakraborti, Anuradha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940489/
https://www.ncbi.nlm.nih.gov/pubmed/31564085
http://dx.doi.org/10.3350/cmh.2019.0031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940489/
https://www.ncbi.nlm.nih.gov/pubmed/31564085
http://dx.doi.org/10.3350/cmh.2019.0031

Ejemplares similares